Search research articles
Contact Us
Filters
Showing results (501-510 of 540) with videos related to
Page
of 54
Sort By:
Hepatobiliary & Pancreatic Diseases International : HBPD INT
|
November 6, 2003
Venovenous bypass ahead of mobilization of the liver in orthotopic liver transplantation
Lu-Nan Yan, Wei Wang, Bo Li, et al.
Gastroenterology
|
June 15, 2016
Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir
Christoph Sarrazin, Hadas Dvory-Sobol, Evguenia S Svarovskaia, et al.
Nature Cell Biology
|
September 13, 2016
Protein kinase C controls lysosome biogenesis independently of mTORC1
Yang Li, Meng Xu, Xiao Ding, et al.
Nature Communications
|
July 21, 2021
TGFβ promotes fibrosis by MYST1-dependent epigenetic regulation of autophagy
Ariella Zehender, Yi-Nan Li, Neng-Yu Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 6, 2016
Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors
Jeffrey R Infante, Antoine Hollebecque, Sophie Postel-Vinay, et al.
Bioorganic & Medicinal Chemistry Letters
|
March 29, 2018
Discovery of 4-ethoxy-7H-pyrrolo[2,3-d]pyrimidin-2-amines as potent, selective and orally bioavailable LRRK2 inhibitors
Xiao Ding, Luigi Piero Stasi, Ming-Hsun Ho, et al.
Hepatology (Baltimore, Md.)
|
October 15, 2014
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus
Eric M Yoshida, Mark S Sulkowski, Edward J Gane, et al.
Nature Biotechnology
|
December 11, 2024
Intestinal mucosal barrier repair and immune regulation with an AI-developed gut-restricted PHD inhibitor
Yanyun Fu, Xiao Ding, Man Zhang, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
October 19, 2019
MEIS2C and MEIS2D promote tumor progression via Wnt/β-catenin and hippo/YAP signaling in hepatocellular carcinoma
Lei Guan, Ting Li, Nanping Ai, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 8, 2018
5-Substituted-N-pyridazinylbenzamides as potent and selective LRRK2 inhibitors: Improved brain unbound fraction enables efficacy
Xiao Ding, Luigi Piero Stasi, Xuedong Dai, et al.
Page
of 54
Search research articles
Search
Showing results (501-510 of 540) with videos related to
Sort By:
Page
of 54
Hepatobiliary & Pancreatic Diseases International : HBPD INT
|
November 6, 2003
Venovenous bypass ahead of mobilization of the liver in orthotopic liver transplantation
Lu-Nan Yan, Wei Wang, Bo Li, et al.
Gastroenterology
|
June 15, 2016
Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir
Christoph Sarrazin, Hadas Dvory-Sobol, Evguenia S Svarovskaia, et al.
Nature Cell Biology
|
September 13, 2016
Protein kinase C controls lysosome biogenesis independently of mTORC1
Yang Li, Meng Xu, Xiao Ding, et al.
Nature Communications
|
July 21, 2021
TGFβ promotes fibrosis by MYST1-dependent epigenetic regulation of autophagy
Ariella Zehender, Yi-Nan Li, Neng-Yu Lin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 6, 2016
Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors
Jeffrey R Infante, Antoine Hollebecque, Sophie Postel-Vinay, et al.
Bioorganic & Medicinal Chemistry Letters
|
March 29, 2018
Discovery of 4-ethoxy-7H-pyrrolo[2,3-d]pyrimidin-2-amines as potent, selective and orally bioavailable LRRK2 inhibitors
Xiao Ding, Luigi Piero Stasi, Ming-Hsun Ho, et al.
Hepatology (Baltimore, Md.)
|
October 15, 2014
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus
Eric M Yoshida, Mark S Sulkowski, Edward J Gane, et al.
Nature Biotechnology
|
December 11, 2024
Intestinal mucosal barrier repair and immune regulation with an AI-developed gut-restricted PHD inhibitor
Yanyun Fu, Xiao Ding, Man Zhang, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
October 19, 2019
MEIS2C and MEIS2D promote tumor progression via Wnt/β-catenin and hippo/YAP signaling in hepatocellular carcinoma
Lei Guan, Ting Li, Nanping Ai, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 8, 2018
5-Substituted-N-pyridazinylbenzamides as potent and selective LRRK2 inhibitors: Improved brain unbound fraction enables efficacy
Xiao Ding, Luigi Piero Stasi, Xuedong Dai, et al.
Page
of 54